EnhanceMD review: the first month and later tier prices differ sharply

The recurring figure is the useful comparison

The opening lists a semaglutide tier at $49 initially and $212 per month afterward. Its tirzepatide tier is $99 initially and $280 afterward. A combination tier has its own introductory and later price. Comparing only the opening month would obscure the main ongoing expense. Each tier should be evaluated as the actual selected purchase, including commitment and cancellation terms.

Sources: Metabolic Reset Program with GLP-1 & NAD+ Therapy | Enhance.MD

Four weeks is not a calendar-month equivalence

The page refers to a four-week medication supply alongside monthly pricing. A reader should keep those units visible rather than assume every refill corresponds to a calendar month. We have not verified a complete order cycle or supplied package. The practical commercial question is how payment and fulfillment periods line up in the selected plan.

Sources: Metabolic Reset Program with GLP-1 & NAD+ Therapy | Enhance.MD

For another purchase structure, read Shed and CoreAge Rx. These links compare the offers, not individual health outcomes.

Combination marketing is not a benefit finding

EnhanceMD markets a tier combining semaglutide and tirzepatide-related treatment. The public offer does not establish that the combination is clinically preferable or appropriate for a particular patient. We do not recommend it, translate its label into a regimen or transfer single-product trial results to it. The prescribing clinician must explain the exact preparation and clinical justification.

Sources: Metabolic Reset Program with GLP-1 & NAD+ Therapy | Enhance.MD

Ongoing care claims need their own scope

The page describes provider access and periodic laboratory-related support. These are included-service claims rather than a clinical interaction we observed. A reader should clarify which tests and follow-up contacts apply to their selected tier. More advertised components do not automatically establish better outcomes, and a low opening price does not settle the total cost of sustained care.

Sources: Metabolic Reset Program with GLP-1 & NAD+ Therapy | Enhance.MD

Keep the full cost calculation and branded-versus-compounded distinction visible. Our evidence guide explains why different result types cannot be scored as one clinical ranking.

Keep the clinical question separate

NIDDK explains that prescription weight-management treatment is intended for people with relevant health circumstances and requires a professional assessment. A convenient website does not determine that assessment. This article cannot decide whether treatment is appropriate for a reader, compare individual risks or forecast weight change. The clinician needs the actual medical history and should explain the selected product and follow-up plan.

Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK

Where this review ends

This review was written from official public pages available on October 1, 2026. We did not receive patient care, test medication, inspect a pharmacy or verify a completed purchase. Prices and program descriptions can change. FDA’s warning about unapproved GLP-1 products explains a regulatory distinction; it is not independent validation of this particular provider or product. Individual benefits, risks and eligibility require a qualified clinician.

Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss